Protein palmitoylation and immune regulation in pancreatic ductal adenocarcinoma: Integrating insights from cross-cancer studies
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · 2026-04 · 1881 (2) · 189532
DOI: 10.1016/j.bbcan.2026.189532 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, 2026-04. Verfasst von Xiaotong Cui und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hepatobiliary and Pancreatic Surgery, The Affiliated Hospital of Qingdao University, Qingdao, China. Hauptthemen laut MEDLINE: Carcinoma, Pancreatic Ductal, Lipoylation, Pancreatic Neoplasms. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 285 Literaturangaben.
Abstract (Originalsprache)
Pancreatic ductal adenocarcinoma (PDAC) is characterized by an immunologically "cold" tumor microenvironment (TME), marked by a dense stromal barrier, impaired antigen presentation, and extensive infiltration of immunosuppressive cells. In recent years, protein S-palmitoylation, a reversible lipid modification, has emerged as a critical mechanism regulating immune signaling, receptor trafficking, and membrane localization of immune-related proteins. This review highlights the multifaceted roles of S-palmitoylation in shaping the immunological landscape of PDAC. We systematically discuss its involvement in immune checkpoint regulation, T-cell activation, antigen presentation, and the function of myeloid-derived suppressor cells (MDSCs), integrating evidence from both PDAC and other cancer types. Special attention is given to key palmitoylated molecules, including programmed death-ligand 1 (PD-L1), cluster of differentiation 80 (CD80), lymphocyte-specific protein tyrosine kinase (LCK), linker for activation of T cells (LAT), interferon-induced transmembrane proteins (IFITMs), and major histocompatibility complex class I (MHC-I), and their potential roles in the immunosuppressive network of PDAC. Moreover, we explore therapeutic strategies targeting palmitoylation, such as the use of selective palmitoyltransferase inhibitors, the design of palmitoylation-deficient CAR-T cells, and the development of nanotechnology-based delivery platforms. By incorporating cross-cancer insights, we propose that palmitoylation is a promising regulatory axis for reprogramming the PDAC immune microenvironment and overcoming resistance to immunotherapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Hepatobiliary and Pancreatic Surgery, The Affiliated Hospital of Qingdao University, Qingdao, China.
- Prenatal Diagnosis Center, the Affiliated Hospital of Qingdao University, 16 Jiangsu Road, Qingdao 266003, China.
- Department of Oncology Medicine, The Affiliated Hospital of Qingdao University, Qingdao 266002, Shandong Province, China. Electronic address: 470383039@qq.com.
- Department of Hepatobiliary and Pancreatic Surgery, The Affiliated Hospital of Qingdao University, Qingdao, China. Electronic address: wangzusen@126.com.
Zitieren
APA
Cui, X., Li, C., Zhong, X., Sun, A., Lan, Y., & Wang, Z. (2026). Protein palmitoylation and immune regulation in pancreatic ductal adenocarcinoma: Integrating insights from cross-cancer studies. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, 1881(2), 189532. https://doi.org/10.1016/j.bbcan.2026.189532
Vancouver
Cui X, Li C, Zhong X, Sun A, Lan Y, Wang Z. Protein palmitoylation and immune regulation in pancreatic ductal adenocarcinoma: Integrating insights from cross-cancer studies. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer. 2026;1881(2):189532. doi:10.1016/j.bbcan.2026.189532
BibTeX
@article{Cui2026,
author = {Cui, Xiaotong and Li, Changlei and Zhong, Xue and Sun, Ao and Lan, Yingying and Wang, Zusen},
title = {Protein palmitoylation and immune regulation in pancreatic ductal adenocarcinoma: Integrating insights from cross-cancer studies},
journal = {Biochimica et Biophysica Acta (BBA) - Reviews on Cancer},
year = {2026},
volume = {1881},
number = {2},
pages = {189532},
doi = {10.1016/j.bbcan.2026.189532}
}
EUVIMED